Qlife Holding – Company introduction
Meet Qlife’s CEO Thomas Warthoe presenting an introduction to the company. The event takes place on the 26th of October at 1 pm CET.
Qlife’s home diagnostic platform Egoo Health addresses the following trends within healthcare:
- Healthcare decentralization
- Chronic diseases in the increasing ageing population
- Lifestyle diseases
In the trend for home diagnostics, the company offers a very compelling solution, Qlife already has it CE approved with sales today; the next step is chronic diseases with a market potential of more than 50 mio. patients in the EU, and ultimately sales directly to all people and consumers.
Qlife Holding AB is a med-tech group that strives to revolutionize the market for clinical biomarkers and virus tests. By enabling tests at home as a complement to tests in healthcare, access to important health information is facilitated, which can contribute to better treatment and potentially prevent diseases. Qlife Holding was formed in October 2019 and received the certification ISO 13485:2016 the same year, which means that Qlife meets all requirements for the manufacture and sale of in-vitro diagnostic analyzers and reagents. The first capsules in the company's product, Egoo.Health Platform, was CE marked for professional use in early 2020. The company has patent protection for key parts of its technology.
Qlife Holding AB is listed on Nasdaq First North Stockholm with the ticker QLIFE.
HC Andersen Capital receives payment from Qlife for a Corporate Visibility/Digital IR subscription agreement. /Claus Thestrup 4.55PM 12-oct-2022.